宠物癌症药物市场规模、份额和成长分析（按类型、治疗方法、给药途径、癌症类型和地区划分）—2026-2033年产业预测

预计到 2024 年，宠物癌症药物市场规模将达到 4.414 亿美元，到 2025 年将达到 4.8466 亿美元，到 2033 年将达到 10.2389 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.8%。

宠物癌症治疗市场正经历显着成长，反映出人们对宠物医疗保健进步的日益关注。随着宠物饲主越来越重视爱宠的健康，对有效癌症治疗方法的需求也随之增加。这一增长源于人们对宠物健康的日益重视，以及对提供最佳护理至关重要的认识。主要市场参与者正致力于研发专为宠物设计的创新治疗方法，从而提高宠物确诊后的生存率和生活品质。此外，兽医肿瘤学的进步也加深了人们对宠物癌症的了解，并推动了标靶治疗方案的发展。总而言之，该市场体现了关怀与科学创新的动态交汇，致力于满足我们挚爱伴侣动物的特殊医疗保健需求。

宠物癌症药物市场驱动因素

推动宠物癌症治疗市场成长的关键因素之一是宠物人性化趋势的日益增强。随着宠物饲主越来越将动物视为珍贵的家庭成员，他们也更愿意投资先进的医疗保健方案，例如癌症治疗。这种观念的转变正在推动对专为宠物设计的高效且人性化的癌症治疗方法的需求。因此，这一趋势正在促进行业创新并刺激市场扩张。各公司正致力于开发先进的解决方案，以满足宠物饲主不断变化的需求，帮助他们确保爱宠的健康和福祉。

宠物癌症药物市场的限制

宠物癌症治疗市场面临的一大限制因素是宠物癌症治疗带来的沉重经济负担。包括诊断、手术、放射治疗和药物在内的各种医疗干预措施的高昂费用，可能会阻碍饲主为他们心爱的宠物寻求先进的治疗方案。这种经济负担迫使许多饲主在他们愿意提供的护理水平上做出艰难的抉择，最终可能会阻碍宠物获得可能挽救生命的治疗。因此，儘管人们对这些治疗方法的认识和需求都在不断增长，但经济承受能力问题仍然严重影响市场动态和有效治疗方案的可近性。

宠物癌症治疗市场趋势

宠物癌症治疗市场正呈现出显着的趋势，即采用个人化治疗策略来满足每隻宠物的独特需求。饲主主人和兽医越来越意识到不同动物物种的癌症类型和治疗反应存在差异，这推动了对客製化治疗方案的需求。诊断技术的创新，包括基因谱分析和分子检测，为精准的癌症诊断奠定了基础，并推动了针对每隻宠物癌症特征的标靶治疗的开发。这种转变不仅提高了治疗效果，还最大限度地减少了副作用，体现了兽医肿瘤学领域致力于提升医疗品质和改善患者预后的坚定决心。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管分析

全球宠物癌症药物市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 狗
• 猫
• 其他物种

全球宠物癌症药物市场规模（按疗法和复合年增长率划分）（2026-2033 年）

• 化疗
• 免疫疗法
• 标靶治疗
• 联合治疗

全球宠物癌症药物市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 注射

全球宠物癌症治疗市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 淋巴瘤
• 肥大细胞瘤
• 黑色素瘤
• 乳腺腺癌和鳞状细胞癌
• 其他癌症

全球宠物癌症治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Elanco Animal Health（US）
• Anivive Lifesciences（US）
• Regeneus（Australia）
• Qbiotics（Australia）
• Zoetis（US）
• VetDC（US）
• AB Science（France）
• Vet Cancer Group（US）
• VetriScience（US）
• Vetnostics（Australia）
• Veterinary Cancer Society（US）
• PetCure Oncology（US）
• Oasmia Pharmaceutical（Sweden）

结论与建议

Pet Cancer Therapeutics Market size was valued at USD 441.4 Million in 2024 and is poised to grow from USD 484.66 Million in 2025 to USD 1023.89 Million by 2033, growing at a CAGR of 9.8% during the forecast period (2026-2033).

The pet cancer therapeutics market is experiencing significant growth, reflecting an increasing focus on advancements in pet healthcare. As pet owners prioritize their companions' health, there is rising demand for effective cancer treatment options. This surge is fueled by a heightened awareness of pet health and an understanding that providing optimal care is crucial. Key market players are innovating with new therapies designed specifically for pets, enhancing their chances of survival and quality of life post-diagnosis. Additionally, developments in veterinary oncology are enabling a deeper understanding of pet cancers, leading to the creation of targeted treatment solutions. Overall, the market represents a dynamic intersection of compassion and scientific innovation, addressing the specialized healthcare needs of cherished pets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pet Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pet Cancer Therapeutics Market Segments Analysis

Global Pet Cancer Therapeutics Market is segmented by Species, Therapy, Route of Administration, Cancer Type and region. Based on Species, the market is segmented into Dogs, Cats and Other species. Based on Therapy, the market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and Combination therapy. Based on Route of Administration, the market is segmented into Oral and Injection. Based on Cancer Type, the market is segmented into Lymphoma, Mast cell cancer, Melanoma, Mammary and squamous cell cancer and Other cancer types. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pet Cancer Therapeutics Market

A significant factor propelling the growth of the pet cancer therapeutics market is the growing trend of pet humanization. As pet owners increasingly regard their animals as cherished family members, their readiness to invest in sophisticated healthcare options, such as cancer treatments, has intensified. This shift in perception has led to a heightened demand for effective and compassionate cancer therapies designed specifically for pets. Consequently, this trend fosters innovation within the industry and stimulates market expansion, as companies strive to develop advanced solutions that cater to the evolving needs of pet owners committed to ensuring the health and well-being of their beloved companions.

Restraints in the Pet Cancer Therapeutics Market

A notable limitation within the pet cancer therapeutics market is the considerable financial burden presented by cancer treatments for pets. The high costs associated with various medical interventions, such as diagnostics, surgical procedures, radiation therapy, and medications, can deter pet owners from pursuing advanced care options for their beloved animals. This financial strain may force many to make challenging decisions regarding the level of treatment they can provide, ultimately hindering their access to potentially life-saving therapies. Consequently, despite a growing awareness and demand for these therapeutics, the issue of affordability significantly influences market dynamics and the availability of effective treatments for pets.

Market Trends of the Pet Cancer Therapeutics Market

The pet cancer therapeutics market is experiencing a pronounced trend toward personalized treatment strategies that cater to the unique needs of individual pets. Pet owners and veterinarians are increasingly acknowledging the variance in cancer types and treatment responses among different animals, which is prompting a heightened demand for customized therapeutic solutions. Innovations in diagnostics, including genetic profiling and molecular testing, are paving the way for accurate cancer diagnoses, allowing for the development of targeted therapies that align with the specific characteristics of each pet's cancer. This shift not only enhances treatment efficacy but also minimizes adverse effects, demonstrating a robust commitment to improving care quality and patient outcomes in veterinary oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis

Global Pet Cancer Therapeutics Market Size by Species & CAGR (2026-2033)

• Market Overview
• Dogs
• Cats
• Other species

Global Pet Cancer Therapeutics Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Global Pet Cancer Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injection

Global Pet Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

Global Pet Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Species, Therapy, Route of Administration, Cancer Type)
  • US
  • Canada
• Europe (Species, Therapy, Route of Administration, Cancer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Species, Therapy, Route of Administration, Cancer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Species, Therapy, Route of Administration, Cancer Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Species, Therapy, Route of Administration, Cancer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations